Trial Profile
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2019
Price :
$35
*
At a glance
- Drugs Etokimab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors AnaptysBio
- 10 Feb 2019 Status changed from active, no longer recruiting to completed.
- 29 May 2018 According to an AnaptysBio media release, clinical data from this study was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018.
- 29 May 2018 Results presented in the AnaptysBio media release.